• 1
    Caldwell J, Gendreau RM, Furst D. A pilot study using a staph protein A column (Prosorba®) to treat refractory rheumatoid arthritis. J Rheumatol. In press.
  • 2
    Wiesenhutter CW, Irish BL, Bertram JH. Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a pilot trial. J Rheumatol 1994; 213: 80412.
  • 3
    Langone JJ. Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by Streptococci and Pneumonococci. Adv Immunol 1982; 32: 157252.
  • 4
    Haas H, Havel A, Lange A, Gross W, Flad HD, Schlaak M. Circulating immune complexes and NK activity in systemic lupus erythematosus. Immun Infekt 1984; 12: 10910.
  • 5
    Highton J, Panayi GS, Shepherd P, Wooley P. Effect of sera from patients with rheumatoid arthritis on normal lymphocytes: a possible immunoregulatory role for immune complexes. Ann Rheum Dis 1982; 41: 5638.
  • 6
    Snyder HW, Balint JP, Jones FR. Modulation of immunity in patients with autoimmune disease and cancer treated by extracorporeal immunoadsorption with PROSORBA® columns. Semin Hematol 1989; 26 Suppl 1: 3141.
  • 7
    American Medical Association Panel. Current status of therapeutic plasmapheresis and related techniques: report of the A.M.A. panel on therapeutic plasmapheresis. JAMA 1985; 253: 81925.
  • 8
    Rothwell RS, Davis P, Gordon PA, Dasgupta MK, Johny KV, Russell AS, et al. A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis. Arthritis Rheum 1980; 23: 78590.
  • 9
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 10
    Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion 1994; 34: 8914.
  • 11
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 12
    Whitehead J. The design and analysis of sequential clinical trials. 2nd ed. Sussex (UK): Ellis Horwood Limited; 1992.
  • 13
    Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 193340.
  • 14
    Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 48194.
  • 15
    Anderson JJ, Wells G, Verohoeven AC, Felson DT. Factors affecting response to treatment in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheum 1998; 41 Suppl 9: S344.
  • 16
    Mold C, Tamerius JD, Phillips G Jr. Complement activation during painful crisis in sickle cell anemia. Clin Immunol Immunopathol 1995; 76: 31420.
  • 17
    Stevens DM, Gartner SL, Pearson RR. Complement activation during saturation diving. Undersea Hyperbaric Med 1993; 20: 27988.